ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

November 5, 2013
ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ’ADCs’, and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.
Read the full press release

Auven Therapeutics Announces AstraZeneca’s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in ADC Therapeutics

October 15, 2013
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs addressing unmet medical needs, today announced that its strategic investment in the antibody-drug conjugate (ADC) field has been validated by the sale of its platform technology portfolio Company Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca.
Read the full press release
Read AstraZeneca’s press release

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

July 15, 2013
ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (ADCs), and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.
Read the full press release

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers

June 24, 2013
VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (ADCs), today announced a licensing deal for a novel antibody against an undisclosed hematological cancer target
Read the full press release

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

June 17, 2013
Genmab A/S (OMX: GEN) and ADC Therapeutics, announced today an agreement to develop a new antibody-drug conjugate (ADC) product.
Read the full press release

Celtic Therapeutics Rebrands as Auven Therapeutics

March 11, 2013
Celtic Therapeutics Management L.L.L.P. (Celtic Therapeutics), the global private equity company focused on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products, has announced a name change to Auven Therapeutics Management L.L.L.P (Auven Therapeutics) effective from March 1, 2013.
Read the full press release